Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

Vertex Pharmaceuticals has outperformed the broader healthcare sector over the past year. Despite a 6.3% drop from its ...

Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...

Market correction impacts JPMorgan Equity Premium Income ETF, but its 7%+ yield & income potential shine amid volatility.